Cystic Fibrosis Screening via IVF in Hong Kong: PGT-M Genetic Testing Process and Conditions

Opening: Real Consultation Scenario

Consultation Scenario　Ms. Li, 29, diagnosed as a carrier of cystic fibrosis (CFTR gene R117H mutation). Her husband was screened and found no pathogenic mutations. The couple plans to have a child through IVF, hoping to avoid passing on the condition. She asks: "Can IVF in Hong Kong really screen out cystic fibrosis? How does it work specifically?"

============================================ Module A: Direct Answer to the Question ============================================

1. Can Cystic Fibrosis Be Screened via IVF in Hong Kong?

Yes, it can be screened. Fertility centers in Hong Kong equipped with third-generation IVF (PGT) technology can perform embryo genetic screening for cystic fibrosis (CF) using PGT-M (Preimplantation Genetic Testing for Monogenic Disorders). The prerequisite is that the pathogenic gene mutation site(s) in the couple or the proband have been clearly identified, and systematic genetic counseling has been completed. PGT-M can select embryos that do not carry the pathogenic gene for transfer, blocking genetic transmission at the source.

============================================ Module C: The Doctor's Perspective ============================================

2. Reproductive Medicine Perspective: The Core Logic of PGT-M Screening for Cystic Fibrosis

Cystic fibrosis is an autosomal recessive genetic disorder caused by mutations in the CFTR gene. When assessing the feasibility of screening, doctors focus on three key points:

• Mutation Clarity: The specific CFTR mutation type (e.g., ΔF508, R117H, G551D, etc.) in the couple or proband must be confirmed through gene sequencing.
• Family Linkage Analysis: Blood samples from the couple and, if necessary, their immediate relatives are needed to construct haplotypes, ensuring the accuracy of embryo testing.
• Laboratory Qualifications: Centers in Hong Kong capable of PGT-M must have experience in single-gene disorder testing, SNP array or NGS platforms, and a genetic counseling team.

============================================ Module I: Actual Process ============================================

3. Actual Process of Screening for Cystic Fibrosis via IVF in Hong Kong

The entire cycle involves five stages: genetic testing, ovarian stimulation, embryo culture, biopsy and genetic analysis, and frozen embryo transfer. The standardized steps are as follows:

Stage	Specific Content	Approximate Time
① Genetic Counseling & Gene Confirmation	A genetic counselor assesses family history, collects blood samples for CFTR whole-exome or targeted region sequencing to identify mutation sites; family linkage analysis is performed if necessary.	3–6 weeks
② Registration & Medical Examination	Both partners complete basic tests including infectious disease screening, AMH, semen analysis, and chromosome karyotyping; sign PGT informed consent.	2–4 weeks
③ Ovarian Stimulation & Egg Retrieval	The woman undergoes ovarian stimulation (approx. 9–12 days), followed by transvaginal ultrasound-guided egg retrieval.	2–3 weeks
④ IVF & Embryo Culture	ICSI fertilization, embryos cultured to blastocyst stage on day 5–6.	5–7 days
⑤ Embryo Biopsy & PGT-M Testing	3–5 cells are biopsied from the trophectoderm of the blastocyst. After whole genome amplification, CFTR mutations and linkage markers are detected using SNP array or NGS.	4–6 weeks
⑥ Frozen Embryo Transfer	Select a blastocyst not carrying the pathogenic gene for thawing and transfer; pregnancy test 10–12 days after transfer.	1–2 days (transfer)

* The total cycle usually takes 3–4 months. If family linkage analysis or gene verification needs to be repeated, it may be extended by 2–4 weeks.

============================================ Module G: Most Easily Overlooked Details ============================================

4. Most Easily Overlooked Details

• Mutation sites must be clearly identified in "pairs": If only one partner is known to be a carrier and the other has not undergone CFTR gene sequencing, PGT-M cannot be performed. The genotypes of both partners must be confirmed first.
• Timing of family sample collection: Linkage analysis requires blood samples from both partners and at least one parent from each side. If parents are deceased or unable to cooperate, it increases the difficulty of testing and may require alternative strategies.
• Residual risk of embryo testing: The accuracy of PGT-M is approximately 97%–99%. There is a very low probability of allele dropout or recombination errors. Prenatal diagnosis is still recommended after transfer for confirmation.
• Differences in testing standards between Hong Kong and Mainland China: Hong Kong laboratories typically follow international standards (ACMG guidelines), but probe panels and data analysis algorithms vary between centers. It is necessary to confirm whether the test covers common CFTR mutations in Asian populations.

============================================ Module J: Time Planning ============================================

5. Time Planning: When to Start Preparing?

It is recommended to start at least 4–5 months in advance. The recommended timeline is as follows:

• Months 1–2: Complete genetic counseling, CFTR gene sequencing, and family linkage analysis; simultaneously conduct fertility assessments (AMH, antral follicle count, semen analysis).
• Month 3: Registration, medical examinations, sign PGT informed consent; begin ovarian stimulation cycle.
• Month 4: Egg retrieval, embryo culture, biopsy, PGT-M testing.
• Month 5: Receive test results, select transferable embryos, and perform frozen embryo transfer.

============================================ Module L: Interpretation of Key Tests ============================================

6. Interpretation of Key Test Indicators

6.1 CFTR Gene Test Report

The report lists the specific mutation site(s) and pathogenicity classification (Pathogenic / Likely Pathogenic / VUS). PGT-M only screens for clearly pathogenic mutations. If a VUS (Variant of Uncertain Significance) is detected, family co-segregation analysis or functional studies are needed to determine whether to include it in the screening.

6.2 Interpretation of Embryo PGT-M Results

Result Category	Meaning	Transfer Recommendation
No pathogenic mutation detected	Embryo does not carry the pathogenic CFTR mutation from either parent	Priority for transfer
Carries pathogenic mutation (heterozygous)	Embryo carries one pathogenic mutation, making it a carrier	Can be transferred or discarded based on patient preference
Carries pathogenic mutations (homozygous or compound heterozygous)	Embryo carries two pathogenic mutations and will develop cystic fibrosis	Not recommended for transfer
Inconclusive / Recombination	Unable to determine definitively due to allele dropout or homologous recombination	Recommend re-evaluation or discard the embryo

* Note: PGT-M cannot detect de novo mutations. If there is no proband in the family and only one partner is a carrier, the probability of a de novo mutation should be assessed.

============================================ Module M: Case Scenario Analysis ============================================

7. Common Scenario Analysis

============================================ Module Q: Frequently Asked Questions ============================================

8. Frequently Asked Questions

• Q: How many embryos are needed for PGT-M screening for cystic fibrosis?
  A: Generally, 5–8 blastocysts are needed to have a higher probability of obtaining a transferable non-carrier embryo. If ovarian reserve is low or few eggs are retrieved, multiple ovarian stimulation cycles may be needed to accumulate embryos.
• Q: What is the approximate cost of PGT-M in Hong Kong?
  A: Including genetic testing, ovarian stimulation, egg retrieval, embryo biopsy, PGT-M analysis, and frozen embryo transfer, the total cost is approximately HKD 120,000–200,000, depending on the center, medication costs, and testing items.
• Q: Is amniocentesis still necessary after screening?
  A: It is recommended. PGT-M is a preimplantation screening and cannot 100% rule out the risk of recombination or allele dropout. Prenatal diagnosis (amniocentesis) remains the gold standard for confirming the fetus's status.
• Q: Which center in Hong Kong has more experience with PGT-M for cystic fibrosis?
  A: Fertility centers at institutions like the University of Hong Kong's Queen Mary Hospital, Hong Kong Sanatorium & Hospital, and Union Hospital offer PGT-M services. However, regarding specific experience with CFTR gene testing, you should directly inquire with the center about their qualifications for single-gene disorder testing and their past case numbers.

============================================ Module R: Practitioner's Observations ============================================

9. Practitioner's Observations

In the cases encountered, two points deserve special attention:

• The genetic counseling phase is often underestimated. Some couples think that "just a blood test for genes is enough," but PGT-M actually requires 4–6 weeks of preliminary work (family linkage analysis) and blood samples from both partners and their parents. If parents are unavailable, more complex haplotype inference strategies are needed, which may affect testing accuracy.
• Ethnic specificity of the CFTR gene. The databases of Hong Kong laboratories mainly cover common mutations in Caucasian populations (e.g., ΔF508). It is necessary to verify in advance whether the coverage of CFTR mutation spectrum in the Chinese population (e.g., R117H, 1898+1G>A) is comprehensive. It is recommended to ask the center for a list of the mutations they can detect.

============================================ Ending: Checklist Reminder ============================================ Bottom Knowledge Graph Coverage Markers (Invisible, for structuring only)